Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?
- PMID: 30430027
- PMCID: PMC6186643
- DOI: 10.21037/jtd.2018.07.84
Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Comment on
-
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.Ann Thorac Surg. 2018 Jul;106(1):178-183. doi: 10.1016/j.athoracsur.2018.02.030. Epub 2018 Mar 14. Ann Thorac Surg. 2018. PMID: 29550207 Free PMC article.
References
-
- Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-99. 10.1016/S1470-2045(14)71207-0 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources